ArticleOncology letters2026
Prognostic analysis and expression patterns of programmed cell death ligand 1 and BRAF V600E in esophageal neuroendocrine carcinoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal neuroendocrine carcinoma (ENEC) is a rare and highly aggressive malignancy. The present study investigated the expression of BRAF V600E and programmed death ligand 1 (PD-L1) and analyzed prognostic factors affecting patient outcomes. A total of 56 patients diagnosed with ENEC at the Affiliated Hospital of North Sichuan Medical College between January 2019, and September 2024 were retrospectively analyzed. Among them, 39 patients received surgery and were tested for BRAF V600E and PD-L1 expression using immunohistochemistry. Survival outcomes were estimated using the Kaplan-Meier method, and prognostic factors were assessed using Cox regression models. BRAF V600E mutations were identified in 12.8% (5/39) of cases, and PD-L1 expression was positive in 15.4% (6/39). In the mixed neuroendocrine carcinoma and squamous cell carcinoma (MiNEC-SCC), the positivity rates for both BRAF V600E and PD-L1 were 33.3% (3/9). Across the entire cohort, the 1-year overall survival (OS) and progression-free survival (PFS) rates were 79.7 and 43.1%, respectively, while the 3-year OS and PFS rates were 49.5 and 25.1%, respectively. Clinical lymph node stage and surgery were notably associated with both OS and PFS. Patients with tumor thickness >1 cm and length >3 cm had markedly worse PFS. Multivariate analysis identified surgery as an independent predictor of improved PFS (P=0.015). Among patients who underwent surgery, postoperative adjuvant therapy was independently associated with improved PFS (P=0.026). In conclusion, BRAF V600E and PD-L1 were more frequently expressed in the MiNEC-SCC compared with small cell neuroendocrine carcinoma. Surgery and postoperative adjuvant therapy were notably associated with improved PFS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.